BioCentury | Jan 15, 2015
Distillery Therapeutics

Therapeutics: κ opioid receptor (KOR; OPRK1); μ opioid receptor (MOR; OPRM1)

...Purdue Pharma L.P. and Shionogi & Co. Ltd. market the KOR and MOR agonist Targin oxycodone/naloxone...
BioCentury | Nov 10, 2014
Clinical News

Targin oxycodone/naloxone regulatory update

...EMA's CHMP recommended approval of Targin oxycodone/naloxone from Mundipharma to treat severe to very severe idiopathic...
...International Ltd. , Cambridge, U.K. Purdue Pharma L.P. , Stamford, Conn. Product: Targin oxycodone/naloxone ( Targiniq ER...
BioCentury | Nov 7, 2014
Politics & Policy

FDA unlikely to pull conventional opioids

...capsules with sequestered naltrexone from Pfizer Inc. (NYSE:PFE); and reformulations of OxyContin oxycodone and Targiniq ER oxycodone/naloxone...
BioCentury | Oct 18, 2014
Company News

FDA approves abuse-deterrent labeling for Embeda

...Pharma L.P. (Stamford, Conn.) markets the other two: a reformulation of OxyContin oxycodone and Targiniq ER oxycodone/naloxone...
BioCentury | Jul 28, 2014
Clinical News

Targiniq ER oxycodone/naloxone regulatory update

...FDA approved an NDA for Targiniq ER oxycodone/naloxone from Purdue to treat pain severe enough to require...
...to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Targiniq ER...
...L.P. , Stamford, Conn. Shionogi & Co. Ltd. (Tokyo:4507), Osaka, Japan Product: Targiniq ER oxycodone/naloxone ( Targin...
BioCentury | Jul 24, 2014
Company News

FDA approves Purdue's abuse-deterrent oxycodone/naloxone

...FDA approved an NDA for Targiniq ER oxycodone/naloxone from Purdue Pharma L.P. (Stamford, Conn.) to treat pain...
...to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Targiniq ER...
...naloxone. Purdue declined to disclose launch plans, including pricing. FDA is requiring postmarketing studies for Targiniq ER...
BioCentury | Dec 9, 2013
Company News

Mundipharma, Shionogi deal

...Shionogi gained exclusive, Japanese rights to develop and commercialize Mundipharma's OxyContin Neo oxycodone and Targin oxycodone/naloxone...
...and sales milestones, plus royalties. OxyContin Neo is an abuse-deterrent, extended-release formulation of oxycodone, and Targin...
BioCentury | Aug 19, 2013
Clinical News

Targin oxycodone/naloxone regulatory update

...Germany's Federal Joint Committee (G-BA) said it plans to assess pain drug Targin oxycodone/naloxone from Mundipharma...
...both are due Feb. 15, 2014. The dossier for Nucynta was previously due Oct. 15. Targin...
...formulation of mu opioid receptor (MOR) agonist. Mundipharma International Ltd. , Cambridge, U.K. Product: Targin oxycodone/naloxone...
BioCentury | Aug 15, 2013
Company News

G-BA to restart Trobalt reassessment

...BioCentury Extra, May 31) . Separately, G-BA said it plans to assess pain drug Targin oxycodone/naloxone...
BioCentury | Feb 2, 2009
Company News

Mundipharma sales and marketing update

...Mundipharma launched Targin oxycodone/naloxone in the U.K. and the Netherlands to treat chronic severe pain and...
Items per page:
1 - 10 of 11